Drugs that contain Lubiprostone
1. Amitiza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5284858 | SUCAMPO PHARMA LLC | Prostaglandins E and anti ulcers containing same |
Jul, 2014
(9 years ago) | |
| US8088934 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
May, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6414016 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(3 years ago) | |
| US8071613 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(3 years ago) | |
| US8114890 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(3 years ago) | |
| US8097649 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(3 years ago) | |
| US6583174 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(3 years ago) | |
| US7417067 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(3 years ago) | |
| US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(1 year, 7 months ago) | |
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(1 year, 5 months ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(1 year, 5 months ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(1 year, 4 months ago) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(4 months from now) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(1 year, 4 months from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(2 years from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-225) | Apr 26, 2021 |
| New Indication(I-670) | Apr 19, 2016 |
Market Authorisation Date: 29 April, 2008
Treatment: Method of relieving or preventing constipation in a human patient with opioid-induced constipation; Method for relieving or treating constipation in a patient with irritable bowel syndrome; Method fo...
Dosage: CAPSULE;ORAL
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
